BEST UNLIMITED TURBO LONG CERTIFICATE - AMGEN | Real-time Euronext Paris 06:53:57 29/04/2024 pm IST | ||
| 7.436 EUR | -0.12% |
|
| Current month | -17.38% | ||
| 1 month | -14.98% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
AMGEN INC.
Latest news about AMGEN INC.
More news
| Date | Price | Change | Volume |
|---|---|---|---|
| 29/24/29 | 7.436 | -0.12% | 41 |
| 26/24/26 | 7.445 | +2.20% | 78 |
| 25/24/25 | 7.285 | -7.27% | 83 |
| 24/24/24 | 7.856 | +0.32% | 96 |
| 23/24/23 | 7.831 | +1.74% | 65 |
Real-time Euronext Paris
Last update April 29, 2024 at 06:53 pm IST
More quotesStatic data
| Product type | Knock-Out without Stop Loss |
|---|---|
| Buy / Sell | CALL |
| Underlying | AMGEN INC. |
| Issuer | 
Société Générale
|
| HH83S | |
| ISIN | DE000SD3F355 |
| Date issued | 01/02/2021 |
| Strike | 192.6 $ |
| Maturity | Unlimited |
| Parity | 10 : 1 |
| Emission price | 6.74 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 13.2 € |
|---|---|
| Lowest since issue | 2.949 € |
| Spread | 0.18 € |
| Spread % | 2.38% |
Company Profile
Amgen Inc. is one of the world's leading biotechnology groups. Net sales break down by source of revenue as follows:
- drug sales (94.2%): drugs for treating cancer, metabolic disorders, bone diseases, renal failure, hemophilia, etc.;
- other (5.8%): primarily royalties.
The United States account for 70.3% of net sales.
Sector
-
Consensus: Amgen Inc.
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
30
Last Close Price
270
USD
Average target price
300.3
USD
Spread / Average Target
+11.22%
- Stock Market
- Certificates
- HH83S Certificat
